Back

Time-Varying Cardiovascular Risk of Febuxostat versus Allopurinol in Gout: A One-stage Meta-analysis

2025-12-30 rheumatology Title + abstract only
View on medRxiv
Show abstract

ObjectivesWhether febuxostat is associated with an increased cardiovascular risk compared to allopurinol in patients with gout remains controversial, with major randomized trials reporting conflicting results. This study aims to perform a comprehensive meta-analysis using reconstructed individual participant data (IPD) to evaluate the time-varying cardiovascular and mortality risk of febuxostat versus allopurinol in gout. MethodsWe conducted a one-stage individual participant data meta-analysis...

Predicted journal destinations